Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Debt / NOTE 2.250% 5/1
-
Market price (% of par)
-
128.16%
-
Total 13F principal
-
$505,179,400
-
Principal change
-
+$671,850
-
Total reported market value
-
$663,088,182
-
Number of holders
-
57
-
Value change
-
+$3,284,695
-
Number of buys
-
22
-
Number of sells
-
24
Institutional Holders of NEUROCRINE BIOSCIENCES INC - NOTE 2.250% 5/1 as of Q1 2020
As of 31 Mar 2020,
NEUROCRINE BIOSCIENCES INC - NOTE 2.250% 5/1 was held by
57 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$505,179,400
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, FRANKLIN RESOURCES INC, Invesco Ltd., WELLS FARGO & COMPANY/MN, BAKER BROS. ADVISORS LP, CALAMOS ADVISORS LLC, MACKAY SHIELDS LLC, Aequim Alternative Investments LP, LAZARD ASSET MANAGEMENT LLC, and WOLVERINE ASSET MANAGEMENT LLC.
This page lists
57
institutional bondholders reporting positions
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.